535 related articles for article (PubMed ID: 22519451)
1. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases: their biological functions and clinical implications.
Hijova E
Bratisl Lek Listy; 2005; 106(3):127-32. PubMed ID: 16026148
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
5. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
Janssens S; Lijnen HR
Cardiovasc Res; 2006 Feb; 69(3):585-94. PubMed ID: 16426591
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
Siasos G; Tousoulis D; Kioufis S; Oikonomou E; Siasou Z; Limperi M; Papavassiliou AG; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1132-48. PubMed ID: 22519444
[TBL] [Abstract][Full Text] [Related]
7. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
Pauschinger M; Chandrasekharan K; Schultheiss HP
Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
[TBL] [Abstract][Full Text] [Related]
8. Structure and function of matrix metalloproteinases and TIMPs.
Nagase H; Visse R; Murphy G
Cardiovasc Res; 2006 Feb; 69(3):562-73. PubMed ID: 16405877
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and atherosclerosis.
Watanabe N; Ikeda U
Curr Atheroscler Rep; 2004 Mar; 6(2):112-20. PubMed ID: 15023295
[TBL] [Abstract][Full Text] [Related]
10. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
[TBL] [Abstract][Full Text] [Related]
11. Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases.
Li X; de Boer OJ; Ploegmaker H; Teeling P; Daemen MJ; de Winter RJ; van der Wal AC
Cardiovasc Pathol; 2016; 25(1):40-6. PubMed ID: 26490693
[TBL] [Abstract][Full Text] [Related]
12. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
Vanhoutte D; Schellings M; Pinto Y; Heymans S
Cardiovasc Res; 2006 Feb; 69(3):604-13. PubMed ID: 16360129
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions.
Varghese S
Front Biosci; 2006 Sep; 11():2949-66. PubMed ID: 16720367
[TBL] [Abstract][Full Text] [Related]
14. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability.
Ruddy JM; Ikonomidis JS; Jones JA
J Vasc Res; 2016; 53(1-2):1-16. PubMed ID: 27327039
[TBL] [Abstract][Full Text] [Related]
15. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Li YY; McTiernan CF; Feldman AM
Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
George SJ
Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722
[TBL] [Abstract][Full Text] [Related]
17. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Krebber MM; van Dijk CGM; Vernooij RWM; Brandt MM; Emter CA; Rau CD; Fledderus JO; Duncker DJ; Verhaar MC; Cheng C; Joles JA
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937927
[TBL] [Abstract][Full Text] [Related]
18. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
Vanhoutte D; Heymans S
J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases.
Zitka O; Kukacka J; Krizkova S; Huska D; Adam V; Masarik M; Prusa R; Kizek R
Curr Med Chem; 2010; 17(31):3751-68. PubMed ID: 20846107
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases in cardiovascular disease.
Liu P; Sun M; Sader S
Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):25B-30B. PubMed ID: 16498509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
